Materias dentro de su búsqueda.
Mostrando 1,621 - 1,640 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.32s Limitar resultados
  1. 1621
    “…Western Blotting of the unaffected (nontumorigenic MCF-12A) and tumorigenic (MCF-7 ER+/PR+/Her2-) breast tissues as well as PCR amplification with the AIPB specific primers of the nontumorigenic and tumorigenic cells showed AIPB expression is maximum with the unaffected breast tissue but reduced in ER+/PR+/Her2- tumors. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
  2. 1622
    “…The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer has propelled the development of HER-targeting monoclonal antibodies (mAb) such as trastuzumab and pertuzumab, which led to dramatic improvements in survival outcomes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
  3. 1623
    “…OBJECTIVES: Extensive application of anti-HER2 targeted therapy improves significantly the HER2-positive advanced breast cancer (BC) prognosis, however, it is still difficult to treat brain metastasis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
  4. 1624
    “…Nevertheless, the biology of HER2-low expression has not reported in gastric cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer
  5. 1625
    “…In addition, Mn-CP demonstrated a noteworthy activity toward OER and HER in acidic media, in contrast to what was observed in 0.1 M KOH.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Electrocatalytic Behavior of an Amide Functionalized Mn(II) Coordination Polymer on ORR, OER and HER
  6. 1626
    “…OBJECTIVE: HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study
  7. 1627
    “…Gastroesophageal cancer (GEC) is an aggressive disease characterized by a high frequency of metastasis and poor overall survival rates. GEC presents HER2 overexpression in 5 to 25% of tumors eligible for HER2-targeted therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The potential of mRNA expression evaluation in predicting HER2 positivity in gastroesophageal cancer
  8. 1628
    “…Here, we performed extensive analyses of the transcriptomic, metabolomic and proteostatic perturbations during the course of treatment of Her2+ breast cancer cells with a Her2 inhibitor covering the drug response, resistance, relapse and drug withdrawal phases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Drug resistance mechanisms create targetable proteostatic vulnerabilities in Her2+ breast cancers
  9. 1629
    “…Gastroesophageal cancers which express human epidermal growth factor 2 (HER2) behave differently to those lacking expression. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis
  10. 1630
    “…Trastuzumab is the cornerstone treatment for HER2-positive breast cancer. While ocular side effects are more commonly described after the use of the antibody-drug conjugate ado-trastuzumab emtansine, we here describe corneal melting in a 79-year-old patient after three cycles of trastuzumab monotherapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer
  11. 1631
    “…SIMPLE SUMMARY: Therapeutic advances in the treatment of HER2-positive metastatic breast cancer have dramatically improved the natural history of these patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
  12. 1632
    “…HER2 is a transmembrane receptor with intrinsic tyrosine kinase activity that is overexpressed in almost 25% of human breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression
  13. 1633
    “…Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is characterized by invasive growth, rapid metastasis and chemoresistance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
  14. 1634
    “…This article reviews the benefits and potential risk of combining radiotherapy and targeted therapy for HER2-positive breast cancer with brain metastases.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
  15. 1635
    “…Further stratified analysis according to molecular subtype revealed that the U-shaped distribution of the HR of BCSD with was only found in the Hormone receptor-positive/HER2-negative (HoR+/HER2-) subgroup. The cumulative incidence plots showed that young age was associated with worse BCSD in the breast cancer patients with stage I-III and HoR+/HER2- subgroup. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups
  16. 1636
    “…Considering HER2 as one of the well-known biomarkers in the cancer field, and published articles regarding serum levels of HER2, in this paper we tried to highlight the issue that most studies don’t stratify the HER-2 concentration of individuals in terms of gender. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Healthy Male Individuals Possess Higher Plasma HER-2 Level than Females
  17. 1637
    “…INTRODUCTION: This study aims to assess safety and effectiveness of pertuzumab in combination with trastuzumab and docetaxel in the neoadjuvant treatment (NeoT) of HER2-positive breast cancer. METHODS: Two consecutive retrospective cohorts (n = 94, 2012–2015 and 2015–2017) of adult women with HER2-positive breast cancer, receiving NeoT at the breast clinic in Portugal (IPO-Porto), were followed. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
  18. 1638
    por Saigle, Victoria
    Publicado 2023
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A patient’s perspective on finding treatment for migraine and a provider who believed her
  19. 1639
    “…HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
  20. 1640
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Fueling the Female Athlete: Auditing Her Representation in Studies of Acute Carbohydrate Intake for Exercise
Herramientas de búsqueda: RSS